Pfizer Inc (PFE): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.3%. By the end of trading, Pfizer rose $0.33 (1.1%) to $31.82 on average volume. Throughout the day, 20,739,383 shares of Pfizer exchanged hands as compared to its average daily volume of 25,855,000 shares. The stock ranged in a price between $31.59-$31.99 after having opened the day at $31.77 as compared to the previous trading day's close of $31.49. Other companies within the Health Care sector that increased today were: BG Medicine ( BGMD), up 22.4%, 22nd Century Group ( XXII), up 19.7%, Bovie Medical Corporation ( BVX), up 15.0% and Relypsa ( RLYP), up 12.4%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $205.7 billion and is part of the drugs industry. Shares are up 2.8% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, IsoRay ( ISR), down 13.1%, Response Genetics ( RGDX), down 9.4%, Revance Therapeutics ( RVNC), down 8.4% and Foundation Medicine ( FMI), down 8.1% , were all laggards within the health care sector with Incyte ( INCY) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing